perifosine has been researched along with phosphorylcholine in 222 studies
| Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (phosphorylcholine) | Trials (phosphorylcholine) | Recent Studies (post-2010) (phosphorylcholine) |
|---|---|---|---|---|---|
| 245 | 31 | 140 | 5,308 | 255 | 1,893 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (2.70) | 18.2507 |
| 2000's | 72 (32.43) | 29.6817 |
| 2010's | 137 (61.71) | 24.3611 |
| 2020's | 7 (3.15) | 2.80 |
| Authors | Studies |
|---|---|
| Engel, J; Hilgard, P; Klenner, T; Kutscher, B; Nössner, G; Stekar, J | 1 |
| Arndt, D; Fichtner, I; Stahn, R; Zeisig, R | 1 |
| Grieb, S; Knebel, NG; Locher, M; van der Vlis, E; Verheij, ER; Winkler, M | 1 |
| Bartelink, H; Ruiter, GA; van Blitterswijk, WJ; Verheij, M; Zerp, SF | 2 |
| Berger, MR; Eibl, H; Konstantinov, SM | 1 |
| Grosman, N | 1 |
| Ruiter, GA; van Blitterswijk, WJ; Verheij, M; Zerp, SF | 1 |
| Figg, WD; Messmann, R; Sausville, EA; Woo, EW | 1 |
| Boeck, G; Grunicke, H; Hofmann, J; Knebel, NG; Rybczynska, M; Spitaler, M | 1 |
| Gutkind, JS; Lahusen, T; Patel, V; Sausville, EA; Senderowicz, AM; Sy, T | 1 |
| Beijnen, JH; Crul, M; de Klerk, GJ; Dubbelman, R; Knebel, NG; Reichert, S; Rosing, H; Schellens, JH; ten Bokkel Huinink, WW; Traiser, M | 1 |
| Dasmahapatra, GP; Kondapaka, SB; Roy, KK; Sausville, EA; Singh, SS | 1 |
| Agresta, M; D'Arrigo, P; Fasoli, E; Losi, D; Pedrocchi-Fantoni, G; Riva, S; Servi, S; Tessaro, D | 1 |
| De Siervi, A; Diggs, J; Marinissen, M; Pages, G; Senderowicz, A; Wang, XF | 1 |
| Alley, MC; Dasmahapatra, GP; Didolkar, P; Ghosh, S; Roy, KK; Sausville, EA | 1 |
| Alberti, D; Arzoomanian, R; Binger, K; Kolesar, J; Marnocha, R; Tutsch, K; Van Ummersen, L; Volkman, J; Wilding, G | 1 |
| Bauer, C; Dai, Y; Dent, P; Grant, S; Payne, SG; Rahmani, M; Reese, E; Spiegel, S | 1 |
| Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR | 1 |
| Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N | 1 |
| Holland, EC; Momota, H; Nerio, E | 1 |
| Arlen, PM; Chen, C; Chung, EJ; Dahut, WL; Daniels, A; Figg, WD; Gulley, J; Jones, E; Lee, MJ; Parnes, HL; Posadas, EM; Sparreboom, A; Steinberg, SM; Trepel, JB; Trout, A; Wright, J | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y; Luwor, R | 1 |
| Mravljak, J; Pecar, S; Zeisig, R | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, T; Ishitsuka, K; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, PG; Yasui, H | 1 |
| Blackstein, M; Bramwell, V; Dancey, J; Dore, N; Eisenhauer, E; Knowling, M; Matthews, S; Tozer, R | 1 |
| Begg, AC; Lagerwerf, S; Mesman, E; Schellens, JH; van Blitterswijk, WJ; Verheij, M; Vink, SR | 1 |
| Ansari, R; Argiris, A; Cohen, E; Dancey, J; Esparaz, B; Karrison, T; Lu, Y; Mauer, A; Pins, M; Vokes, E; Wong, S | 1 |
| Burgan, WE; Camphausen, K; Carter, DJ; de la Peña, L; Hollingshead, MG; Satyamitra, M; Tofilon, PJ | 1 |
| Cappellini, A; Mantovani, I; Martelli, AM; Nyåkern, M | 1 |
| Aldeghi, A; Emanuele, E; Geroldi, D | 1 |
| Bartelink, H; Beijnen, JH; Dubbelman, R; Engel, J; Hillebrand, MJ; Moppi, G; Schellens, JH; Sindermann, H; Verheij, M; Vink, SR | 1 |
| Gajate, C; Mollinedo, F | 1 |
| Bailey, HH; Erlichman, C; Ettinger, DS; Fracasso, PM; Mahoney, MR; Maples, WJ; Okuno, SH; Traynor, AM | 1 |
| Cabrera-Serra, MG; Lorenzo-Morales, J; Piñero, JE; Romero, M; Valladares, B | 1 |
| Benson, AB; Levy, DE; Marsh, Rde W; Mitchell, EP; Rocha Lima, CM; Rowland, KM | 1 |
| Walker, K | 1 |
| Clemons, M; Crump, RM; Dancey, JE; Dent, S; Hedley, D; Leighl, NB; Moore, MJ; Pond, GR; Tozer, R; Vandenberg, TA; Warr, DG | 1 |
| Anderson, KC; Burger, P; Chauhan, D; Fulciniti, M; Ghobrial, IM; Hideshima, T; Leiba, M; Li, XF; Morrison, A; Munshi, NC; Podar, K; Richardson, P; Rumizen, M; Song, W; Tai, YT; Tassone, P | 1 |
| Alder-Baerens, N; Castanys, S; Castanys-Muñoz, E; Gamarro, F; Pomorski, T | 1 |
| Anderson, KC; Bronson, R; Catley, L; Chauhan, D; Hideshima, T; Munshi, NC; Neri, P; Song, W; Tai, YT; Tassone, P | 1 |
| Elrod, HA; Khuri, FR; Lin, YD; Lonial, S; Sun, SY; Wang, X; Yue, P | 1 |
| Klarenbeek, JB; Perrissoud, D; Solary, E; van Blitterswijk, WJ; van der Luit, AH; Verheij, M; Vink, SR | 1 |
| Anderson, KC; Catley, L; Chauhan, D; Hideshima, H; Hideshima, T; Ikeda, H; Kiziltepe, T; Mitsiades, C; Munshi, NC; Ocio, E; Okawa, Y; Podar, K; Raje, N; Richardson, PG; Tai, YT; Vallet, S; Yasui, H | 1 |
| Anderson, KC; Carrasco, R; Farag, M; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Jia, X; Kiziltepe, T; Leleu, X; Lin, CP; McMillin, DW; Moreau, AS; Moreno, D; Ngo, HT; O'Sullivan, G; Pitsillides, CM; Roccaro, A; Runnels, J; Spencer, JA; Treon, SP | 1 |
| Klarenbeek, JB; van Blitterswijk, WJ; van der Luit, AH; Verheij, M; Vink, SR | 1 |
| Billi, AM; Cappellini, A; Chiarini, F; Evangelisti, C; Martelli, AM; Martinelli, G; McCubrey, JA; Ottaviani, E; Papa, V; Ricci, F; Tazzari, PL; Testoni, N | 1 |
| de Vere White, RW; Ghosh, P; Hwa, K; Lara, PN; Pan, CX; Vinall, RL | 1 |
| Castanys, S; Gamarro, F; Muñoz-Martínez, F; Torres, C | 2 |
| Bartelink, H; Budde, M; de Jong, D; Koolwijk, P; Peters, E; Ruiter, GA; van Blitterswijk, WJ; van der Luit, AH; Verheij, M; Vink, SR; Zerp, SF | 1 |
| Birch, R; Carey, MS; Gonzalez-Angulo, AM; Hall, H; Henderson, IC; Hennessy, BT; Kundra, V; Lu, Y; Mills, GB; Poradosu, E; Ravoori, M; Yu, Q; Yu, S | 1 |
| Araujo, DM; Esmaeli, B; Espandar, L; Hatef, E; Kim, SK; Shome, D; Song, CD; Trent, J | 1 |
| Alsayed, Y; Anderson, J; Anderson, KC; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Huston, A; Jia, X; Leleu, X; Moreau, AS; Munshi, N; Ngo, HT; Richardson, P; Roccaro, A; Roodman, DG; Runnels, J; Sportelli, P; Tai, YT; Vallet, S | 1 |
| Cambio, A; Chatta, G; Chee, KG; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Pan, CX; Pinski, J; Quinn, DI; Twardowski, P | 1 |
| Anderson, KC; Azab, A; Azab, F; Brown, M; Burwick, N; Carrasco, DR; Eeckhoute, J; Farag, M; Ghobrial, IM; Hatjiharissi, E; Hideshima, T; Hunter, Z; Jia, X; Leleu, X; Melhem, MR; Moreau, AS; Ngo, HT; Roccaro, AM; Runnels, J; Sacco, A; Treon, SP; Witzig, TE | 1 |
| Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Cappellini, A; Chiarini, F; Del Sole, M; Follo, MY; Gaboardi, GC; Mantovani, I; Martelli, AM; McCubrey, JA; Mongiorgi, S | 1 |
| Floryk, D; Thompson, TC | 1 |
| Dietl, J; Dombrowski, Y; Engel, JB; Grunewald, TG; Häusler, S; Honig, A; Krockenberger, M; Rieger, L; Schönhals, T; Weidler, C; Wischhusen, J | 1 |
| van Blitterswijk, WJ; Verheij, M | 2 |
| Chen, J; David, E; Kaufman, JL; Lonial, S; Sinha, R; Sun, SY | 1 |
| Cabrera-Serra, MG; Piñero, JE; Valladares, B | 1 |
| Ayala, G; Ding, Y; Frolov, A; Harper, JW; Hayes, TG; Ittmann, MM; Kadmon, D; Li, R; Lynch, RG; MacDonnell, V; Miles, BJ; Mims, MP; Thompson, TC; Tsai, MJ; Wheeler, TM; Yan, J | 1 |
| Bontadini, A; Bortul, R; Chiarini, F; Cocco, L; Evangelisti, C; Martelli, AM; Martinelli, G; McCubrey, JA; Papa, V; Ricci, F; Tabellini, G; Tazzari, PL | 1 |
| Fichtner, I; Wenzel, J; Zeisig, R | 1 |
| Liu, W; Poradosu, E; Ratain, MJ; Zhang, W | 1 |
| Dennis, PA; Gills, JJ | 1 |
| Cseh, A; Szalay, B; Szebeni, B; Vásárhelyi, B | 1 |
| Dogan, SS; Esmaeli, B | 1 |
| Anderson, KC; Chauhan, D; Hideshima, T; Klippel, S; Laubach, JP; McMillin, DW; Mitsiades, CS; Munshi, NC; Richardson, PG | 1 |
| Fichtner, I; Habedank, S; Haider, W; Wenzel, J; Zeisig, R | 1 |
| Gajate, C; Mollinedo, F; Reis-Sobreiro, M | 1 |
| Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
| Hou, P; Liu, D; Liu, Z; Wu, G; Xing, M | 1 |
| Elrod, HA; Khuri, FR; Sun, SY; Yue, P | 1 |
| Beijnen, JH; de Vries, NA; van Tellingen, O | 1 |
| Broaddus, WC; Fillmore, HL; Kadian, R; Kumar, A; Tye, GW; Van Meter, TE | 1 |
| Fu, L; Khuri, FR; Kim, YA; Lonial, S; Sun, SY; Wang, X; Wu, X; Yue, P | 1 |
| Celeghini, C; Melloni, E; Secchiero, P; Voltan, R; Zauli, G | 1 |
| Bojdani, E; Hou, P; Xing, M | 1 |
| Sun, SY | 1 |
| Berdel, W; Engel, J; Hanauske, AR; Mross, K; Sindermann, H; Unger, C | 1 |
| Anderson, KC; Azab, AK; Azab, F; Chuma, S; Ghobrial, IM; Harris, B; Hong, F; Jia, X; Leduc, R; Leleu, X; Richardson, PG; Roccaro, A; Rodig, S; Rourke, M; Rubin, N; Sacco, A; Sportelli, P; Varticovski, L; Warren, D; Weller, E | 1 |
| Celeghini, C; Gattei, V; Rimondi, E; Voltan, R; Zauli, G | 1 |
| Atkinson, RL; Rosen, JM; Zhang, M | 1 |
| Albrecht, S; Becher, OJ; Gall, S; Hambardzumyan, D; Helmy, K; Hiner, RL; Holland, EC; Huse, JT; Jabado, N; MacDonald, TJ; Nazarian, J; Walker, TR | 1 |
| Bhatt, AP; Bhende, PM; Damania, B; Dittmer, DP; Roy, D; Sin, SH | 1 |
| Fram, NR; Keenan, JD; Margolis, TP; McLeod, SD; Strauss, EC | 1 |
| Balkaran, S; Daudignon, A; Fernandez, J; Hautecoeur, A; Hivert, B; Lai, JL; Leleu, X; Lepelley, P; Morel, P; Poulain, S; Rossignol, J; Roumier, C; Soenen, V; Wemeau, M | 1 |
| Anderson, KC; Cirstea, D; Desai, N; Gorgun, G; Hideshima, T; Ikeda, H; Kapoor, S; Mukherjee, S; Munshi, NC; Patel, K; Perrone, G; Pozzi, S; Raje, N; Rodig, S; Santo, L; Sportelli, P; Vali, S; Vallet, S | 1 |
| Dietl, J; Engel, JB; Häusler, S; Honig, A; Horn, E; Köster, F; Krockenberger, M; Schmidt, M; Schönhals, T; Wischhusen, J | 1 |
| Carrasco, MP; Jiménez-López, JM; Marco, C; Ríos-Marco, P; Segovia, JL | 1 |
| Brodeur, GM | 1 |
| Li, Z; Liewehr, DJ; Steinberg, SM; Tan, F; Thiele, CJ | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Seeber, S | 1 |
| Cerna, D; Coleman, CN; Falduto, MT; John-Aryankalayil, M; Magnuson, SR; Palayoor, ST; Simone, CB | 1 |
| Chae, S; Kim, B; Kim, DH; Kim, Y; Lucas, A; Rivera-Pabon, O | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Schmidt-Hieber, M; Thiel, E; Weimann, A | 1 |
| Chen, GZ; Elrod, HA; Fu, L; Khuri, FR; Li, B; Lin, YD; Oh, Y; Shin, DM; Sun, SY; Tao, H; Yue, P | 1 |
| Becher, OJ; Bradbury, MS; Charles, N; Chenevert, TL; Galbán, CJ; Galbán, S; Hambardzumyan, D; Holland, EC; Li, F; Pitter, KL; Rehemtulla, A; Ross, BD; Saeed-Tehrani, O; Tehrani, OS | 1 |
| Li, Z; Nakamura, K; Oh, DY; Thiele, CJ | 1 |
| Chinn, DC; Gandara, DR; Holland, WS; Lara, PN; Mack, PC; Pietri, JE; Tepper, CG | 1 |
| Aicher, B; Blau, IW; Busse, A; Dabrowski, R; Lohneis, P; Reufi, B; Schmidt-Hieber, M; Thiel, E; Tietze-Buerger, C | 1 |
| Fei, HR; Li, XQ; Shi, R; Wang, de C; Wang, FZ | 1 |
| Li, J; Sun, H; Yu, T | 1 |
| Cheng, JQ; Coppola, D; Guo, JP | 1 |
| Boles, NC; George, TC; Goodell, MA; Hall, BE; Lin, KK; Rossi, L | 1 |
| Bendell, JC; Campos, LT; Gardner, L; Hagenstad, C; Hermann, RC; Nemunaitis, J; Richards, DA; Sportelli, P; Vukelja, SJ | 1 |
| Allerton, J; Anderson, KC; Bar, M; Colson, K; Densmore, J; Gardner, L; Ghobrial, IM; Hideshima, T; Irwin, D; Jakubowiak, A; Krishnan, A; Laubach, J; Lonial, S; Martin, T; Munshi, N; Poradosu, E; Raje, N; Richardson, PG; Schlossman, R; Sportelli, P; Wolf, J; Zonder, J | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Liu, D; Liu, R; Xing, M | 1 |
| Kang, J; Montales, MT; Prior, RL; Rahal, OM; Rogers, TJ; Simmen, RC; Wu, X | 1 |
| Ronen, SM; Su, JS; Woods, SM | 1 |
| Li, J; Li, X; Lin, X; Wang, Q; Zhang, P; Zhang, X; Zhao, M | 1 |
| Liu, Z; Xing, M | 1 |
| Liu, YY; Qian, WB; Tong, Y; You, LS | 1 |
| Berger, MR; Konstantinov, SM; Reufsteck, C; Yosifov, DY | 1 |
| Chen, J; Chen, MB; Liu, CY; Lu, PH; Tao, GQ; Wang, LQ; Wu, XY | 1 |
| Atkinson, E; Bast, RC; Coleman, RL; Coombes, KR; Dice, K; Dyer, M; Fu, S; Gershenson, DM; Hennessy, BT; Howard, A; Jackson, E; Ju, Z; Kavanagh, JJ; Kundra, V; Kurzrock, R; Levenback, CF; Li, J; Li, Y; Markman, M; Mills, GB; Ng, CS; Sood, AK; Stemke-Hale, K; Wolf, JK | 1 |
| Koklic, T; Trancar, J | 1 |
| Auernhammer, CJ; Brand, S; Göke, B; Lahm, H; Spöttl, G; Vlotides, G; Zitzmann, K | 1 |
| Anderson, KC; Eng, C; Hideshima, T; Kolesar, J; Richardson, PG | 1 |
| Bi, ZG; Chen, B; Cheng, L; He, L; Ji, C; Su, ZL; Sun, WL; Tu, Y; Xia, JP; Yang, YL; Yang, Z | 1 |
| Angeli, G; Manente, AG; Moro, L; Mutti, L; Pinton, G | 1 |
| Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T | 1 |
| Cho, DC; Figlin, RA; Flaherty, KT; Hutson, TE; Michaelson, MD; Puzanov, I; Richards, P; Samlowski, W; Somer, B; Sosman, JA; Sportelli, P; Vogelzang, NJ | 1 |
| Abu-Asab, MS; Castillo, SS; Dennis, PA; Gills, JJ; Goldkorn, T; Kozikowski, AP; LoPiccolo, J; Marceau, C; Tsokos, M; Zhang, C | 1 |
| Li, P; Luo, X; Ma, Z; Wang, X; Zhai, S; Zhu, L | 1 |
| Civallero, M; Cosenza, M; Marcheselli, L; Pozzi, S; Sacchi, S | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L | 1 |
| Ho, WL; Wong, H; Yau, T | 1 |
| Chin, A; Ciancaglini, P; de Oliveira, KT; dos Santos, GA; Faça, VM; Falcão, RP; Ferreira, GA; Greene, LJ; Hanash, SM; Izumi, C; Leopoldino, AM; Rego, EM; Scheucher, PS; Simão, AM; Thomé, CH | 1 |
| Ding, HM; Gu, ZP; Li, D; Wang, ZY; Wei, JJ; Yan, SC; Yang, YJ; Yao, C | 1 |
| Markoulides, MS; Regan, AC | 1 |
| Howe, JR; Komorowski, RA; Lal, G; O'Malley, Y; Shilyansky, J; Sugg, SL; Weigel, RJ | 1 |
| Burgeiro, A; Carvalho, FS; Mollinedo, F; Oliveira, PJ; Pereira, CV; Pereira, GC | 1 |
| Liang, S; Liu, D; Luo, X; Sun, Q; Wang, X; Xu, L; Yang, L; Zhao, X | 1 |
| Cho, DC; Srivastava, N | 1 |
| Koklic, T; Mravljak, J; Podlipec, R; Sentjurc, M; Strancar, J | 1 |
| Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R | 1 |
| Jin, Y; Liu, H; Meng, H; Qian, W; Yang, C; Yang, X; You, L | 1 |
| Alam, MM; Joh, EH; Kim, B; Kim, DH; Lee, YS; Park, H | 1 |
| Baer, MR; Bauer, KS; Carroll, M; Fleckinger, S; Gojo, I; Luger, S; Norsworthy, KJ; Perl, A; Sausville, EA; Tidwell, M | 1 |
| Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
| Guo, R; Liang, S; Liu, D; Wang, X; Xu, H; Xu, Z; Yang, L; Zhang, Z | 1 |
| Carlo-Stella, C; Cleris, L; Daidone, MG; Giacomini, A; Gianni, AM; Locatelli, SL; Mitola, S; Righi, M | 1 |
| Liang, L; Shen, J; Wang, C | 1 |
| Bi, M; Dong, Q; Jiao, X; Zhang, D; Zhang, J; Zhong, F | 1 |
| Allgood, SD; Brander, DM; Chen, Y; Davis, ED; Davis, PH; Friedman, DR; Gockerman, JP; Lanasa, MC; Matta, KM; Moore, JO; Sportelli, P; Volkheimer, AD; Weinberg, JB | 1 |
| Abbasi, F; Al Sawah, E; Apte, SM; Bou Zgheib, N; Chen, X; Chon, HS; Judson, PL; Lancaster, JM; Marchion, DC; Ramirez, IJ; Wenham, RM; Xiong, Y | 1 |
| Chen, X; Huang, W; Li, P; Liang, S; Liu, D; Ma, Z; Wang, X; Yang, L; Zhai, S | 1 |
| Freeman, CL; Giles, FJ; Keane, N; Krawczyk, J; O'Dwyer, M; Swords, R | 1 |
| El-Amm, J; Tabbara, IA | 1 |
| Fu, LS; Guo, J; Qin, LS; Sun, G; Xu, J; Yu, ZQ; Zhang, SM; Zhu, J | 1 |
| Orlowski, RZ | 1 |
| Gradziel, CS; Redfield, AG; Roberts, MF; Stec, B; Wang, Y | 1 |
| Chen, X; Fan, Y; Hao, W; Hou, X; Jin, Y; Liu, F; Ma, A; Pang, T; Song, Z; Wang, W; Wang, Y; Zhang, P | 1 |
| Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y | 1 |
| Cavallo, F; Genadieva-Stavric, S; Palumbo, A | 1 |
| Aicher, B; Engel, J; Fensterle, J; Seipelt, I; Teifel, M | 1 |
| Iida, S; Ri, M | 1 |
| Hou, L; Hou, W; Jia, X; Li, X; Liu, H; Wang, H; Zhang, B; Zhang, H; Zhang, J; Zhao, J; Zou, Y | 1 |
| Koklic, T | 1 |
| Fujino, Y; Goto-Koshino, Y; Ohno, K; Tomiyasu, H; Tsujimoto, H | 1 |
| Dedes, KJ; Fink, D; Gutsche, K; Imesch, P; Samartzis, EP; Stucki, M | 1 |
| Chen, CY; Cheng, YW; Hsu, NY; Lee, H; Lee, MC; Wang, YC; Wu, DW; Wu, JY; Wu, TC | 1 |
| Arbuck, SG; Chau, CH; Elsayed, YA; Figg, WD; Headlee, D; Hollingshead, M; Kalnitskiy, M; Melillo, G; Messman, R; Monga, M; Murgo, AJ; Peer, C; Ryan, QC; Sausville, EA; Senderowicz, AM; Shah, A | 1 |
| Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S | 1 |
| Ho, SL; Lavi, E; Singh, R; Souweidane, MM; Zhou, Z | 1 |
| Buchholz, S; Engel, JB; Kwok, CW; Ortmann, O; Seitz, S; Treeck, O | 1 |
| Dakir, EL; Dakir, el H; López-Abán, J; Mollinedo, F; Muro, A; Varela-M, RE; Yepes, E | 1 |
| Cabello, J; Mohler, WA; Mollinedo, F; Reis-Sobreiro, M; Rodríguez-Matellán, AG; Sáenz-Narciso, B; Sánchez-Blanco, A | 1 |
| Hashimoto, K; Hisamatsu, T; Isobe, A; Kawano, M; Kimura, T; Kuroda, H; Mabuchi, S; Matsumoto, Y; Sasano, T; Sawada, K; Takahashi, R; Testa, JR | 1 |
| Hong, Y; Shen, J; Zhang, J | 1 |
| Ho, SL; Pisapia, DJ; Singh, R; Souweidane, MM; Zhou, Z | 1 |
| Cole, DE; Lester-McCully, CM; Warren, KE; Widemann, BC | 1 |
| Cani, A; Capitani, S; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Tabellini, G; Ultimo, S; Zauli, G | 1 |
| Chen, R; Hu, G; Hu, J; Liu, J; Liu, W; Ning, R; Wang, Y; Wu, L; Xiong, J; Yang, J | 1 |
| Carrasco, MP; Jiménez-López, JM; Marco, C; Ríos, A; Ríos-Marco, P | 1 |
| Koklic, T; Mravljak, J; Orthmann, A; Podlipec, R; Šentjurc, M; Štrancar, J; Testen, A; Zeisig, R | 1 |
| Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW | 1 |
| Boratyn, E; Durbas, M; Horwacik, I; Kamycka, E; Rokita, H | 1 |
| Hong, Y; Shen, J; Zhang, JL; Zhao, Q | 1 |
| Friedman, DR; Hagiopian, MM; Holohan, B; Huang, E; Lai, TP; Shay, JW; Wright, WE | 1 |
| Li, Y; Lu, H; Sheng, Z; Xu, B; Zheng, K | 1 |
| Ishimaru, Y; Narahara, S; Sakamoto, A; Sugiuchi, H; Yamaguchi, R; Yamaguchi, Y; Yamamoto, T | 1 |
| Aréchiga-Figueroa, IA; Delgado-Ramírez, M; Morán-Zendejas, R; Ramírez-Martínez, JF; Rodríguez-Menchaca, AA; Toro-Castillo, C | 1 |
| Shen, J; Xu, L; Zhao, Q | 1 |
| Gajate, C; Legarda-Ceballos, AL; López-Abán, J; Mollinedo, F; Muro, A; Rojas-Caraballo, J; Ruano, AL; Yepes, E | 1 |
| Basu, EM; Becher, OJ; Cheung, NV; Dunkel, IJ; Kramer, K; Kushner, BH; Modak, S; Roberts, SS | 1 |
| Chen, F; Ji, F; Liu, W; Mao, L; Wang, S; Xie, Y | 1 |
| López-Arencibia, A; Lorenzo-Morales, J; Maciver, SK; Martín-Navarro, C; Piñero, JE; Reyes-Batlle, M; Sifaoui, I; Wagner, C | 1 |
| Dong, Y; Gu, X; Hua, Z; Li, Z; Liu, Z; Thiele, CJ; Tian, W; Zhan, Y; Zhang, X | 1 |
| Chanvorachote, P; Pongrakhananon, V; Srinual, S | 1 |
| Cruz, R; Figg, WD; League-Pascual, JC; Lester-McCully, CM; Peer, CJ; Rodgers, L; Ronner, L; Shandilya, S; Warren, KE | 1 |
| André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S | 1 |
| Egler, J; Lang, F | 1 |
| Chin, M; Kato, K; Kawamoto, H; Kosaka, Y; Matsumoto, K; Mugishima, H; Shichino, H | 1 |
| Becher, OJ; Cheung, NV; De Braganca, KC; Dunkel, IJ; Gilheeney, SW; Haque, S; Huse, JT; Khakoo, Y; Kolesar, JM; Kramer, K; Kushner, BH; Lyden, DC; Millard, NE; Modak, S; Spasojevic, I; Trippett, TM | 1 |
| Joghataei, MT; Ramezani Kapourchali, F; Ramezani, S; Vousooghi, N | 1 |
| Chen, L; Dong, J; Kai, J; Wang, Q; Wu, M; Zeng, LH; Zhu, F | 1 |
| Aoki, D; Aoki, Y; Hasegawa, K; Kagabu, M; Kamiura, S; Kimura, T; Mabuchi, S; Mizuno, M; Ochiai, K; Oda, K; Okamoto, A; Saito, T; Takehara, K; Yamaguchi, S; Yunokawa, M | 1 |
| Haniuda, M; Hosokawa, Y; Hyodo, T; Karnan, S; Konishi, H; Ota, A; Tsuzuki, S; Wahiduzzaman, M; Yamaji, M | 1 |
| Cui, S; Ge, RL; Ji, L; Li, Z; Ma, J; Zhao, C | 1 |
| Cartagena-Rivera, AX; Chadwick, RS; Logue, JS | 1 |
| Cheng, H; Li, L; Liu, W; Xin, Q; Ya, B; Yu, T | 1 |
| Adhami, VM; Ateeq, B; Choudhry, H; Hamid, A; Khan, MI; Khan, Q; Mukhtar, H; Rath, S; Siddiqui, IA; Zamzami, MA | 1 |
| Bell, S; Benham, AM; Brown, AP; Carne, NA; Flagler, MJ; Määttä, A | 1 |
| Chahud, F; Ciancaglini, P; Dos Santos, GA; Faça, VM; Ferreira, GA; Leopoldino, AM; Rego, EM; Scheucher, PS; Silva, CLA; Simão, AMS; Thomé, CH | 1 |
| Chen, Y; Huang, J; Kim, W; Lee, S; Liu, J; Lou, Z; Luo, K; Nowsheen, S; Song, Z; Tu, X; Yuan, J; Zhou, Q | 1 |
| Bjune, K; Naderi, S; Wierød, L | 1 |
| Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS | 1 |
| Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI | 1 |
| Feng, H; Li, WJ; Liao, HH; Mou, SQ; Tang, QZ; Wu, HM; Xia, H; Zhang, N; Zhou, ZY | 1 |
| Gaillard, B; Lebeau, L; Pons, F; Remy, JS | 1 |
| He, N; Lv, Z; Wang, S; Zhao, W | 1 |
| Imano, M; Morii, Y; Nishida, S; Otubo, R; Satou, T; Seki, S; Shimomura, K; Takeda, T; Tsubaki, M; Yamatomo, Y | 1 |
| Fujisawa, M; Matsukawa, A; Ohara, T; Tong, G; Yamaguchi, T; Yoshimura, T | 1 |
| Adamová, B; Beneš, P; Navrátilová, J; Pokludová, J; Říhová, K; Šmarda, J | 1 |
17 review(s) available for perifosine and phosphorylcholine
| Article | Year |
|---|---|
Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis.
Topics: Antineoplastic Agents; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phospholipids; Phosphorylcholine; Signal Transduction | 2001 |
Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Neoplasms; Phospholipid Ethers; Phosphorylcholine; Signal Transduction | 2008 |
Perifosine: update on a novel Akt inhibitor.
Topics: Animals; Clinical Trials as Topic; Humans; Membrane Microdomains; Neoplasms; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2009 |
Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.
Topics: Benzamides; Eye Diseases; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Phosphorylcholine; Piperazines; Pyrimidines | 2009 |
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; HSP90 Heat-Shock Proteins; Humans; Immunologic Factors; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines | 2009 |
High-grade glioma mouse models and their applicability for preclinical testing.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Biomarkers, Tumor; Blood-Brain Barrier; Dacarbazine; Disease Models, Animal; Genetic Engineering; Glioblastoma; Mice; Phosphorylcholine; Prognosis; Temozolomide; Transplantation, Heterologous | 2009 |
Enhancing perifosine's anticancer efficacy by preventing autophagy.
Topics: Animals; Antineoplastic Agents; Autophagy; Chloroquine; Drug Synergism; Humans; Lysosomes; Mice; Phosphorylcholine; Protease Inhibitors; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab | 2013 |
Anticancer mechanisms and clinical application of alkylphospholipids.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Endocytosis; Humans; Neoplasms; Organophosphates; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phospholipid Ethers; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quaternary Ammonium Compounds; Signal Transduction | 2013 |
Perifosine in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Molecular Structure; Phosphorylcholine; Randomized Controlled Trials as Topic | 2013 |
Perifosine--a new option in treatment of acute myeloid leukemia?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Molecular Structure; Molecular Targeted Therapy; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Treatment Outcome | 2013 |
Emerging therapies in multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Signal Transduction; Thalidomide | 2015 |
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Acids; Bortezomib; Depsipeptides; Frail Elderly; Glycine; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Oligopeptides; Phosphorylcholine; Proteasome Inhibitors; Pyrazines; Quality of Life; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Current view on the mechanism of action of perifosine in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane; Humans; Lipid Metabolism; Membrane Microdomains; Neoplasms; Neoplastic Stem Cells; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptors, Death Domain; Signal Transduction | 2014 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |
31 trial(s) available for perifosine and phosphorylcholine
| Article | Year |
|---|---|
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Humans; Male; Maximum Allowable Concentration; Middle Aged; Neoplasms; Phosphorylcholine | 2002 |
A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Loperamide; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Phosphorylcholine; Serotonin 5-HT3 Receptor Antagonists; Signal Transduction; Time Factors; Treatment Outcome | 2004 |
Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Chondrocalcinosis; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Melanoma; Middle Aged; Phosphorylcholine | 2005 |
A phase II study of perifosine in androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Humans; Leukapheresis; Male; Middle Aged; Neoplasm Metastasis; Phosphorylcholine; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2005 |
A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial.
Topics: Academies and Institutes; Adult; Aged; Antineoplastic Agents; Canada; Disease Progression; Female; Humans; Male; Middle Aged; Neoplasms; Phosphorylcholine; Sarcoma | 2006 |
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; p38 Mitogen-Activated Protein Kinases; Phospholipids; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2006 |
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Phosphorylcholine; Radiation-Sensitizing Agents | 2006 |
Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Phosphorylcholine; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2006 |
A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antiemetics; Child; Disease Progression; Drug Administration Schedule; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Phosphorylcholine; Survival Analysis | 2007 |
A Phase 2 study of perifosine in advanced or metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Phosphorylcholine; Treatment Outcome | 2008 |
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cell Differentiation; Cell Proliferation; Cell Survival; Cytotoxins; Dexamethasone; Dose-Response Relationship, Drug; Interleukin-6; Lenalidomide; Ligands; Macrophage Colony-Stimulating Factor; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Transplantation; Osteoclasts; Phosphorylcholine; Pyrazines; RANK Ligand; Stromal Cells; Thalidomide; Transplantation, Heterologous; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Corneal Ulcer; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Glucocorticoids; Humans; Imatinib Mesylate; Intestinal Neoplasms; Male; Middle Aged; Phosphorylcholine; Piperazines; Prednisolone; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies | 2008 |
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Topics: Aged; Androgen Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2007 |
Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Flow Cytometry; Histone Acetyltransferases; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; NF-kappa B; Nuclear Receptor Coactivator 3; Phosphorylcholine; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; Trans-Activators | 2008 |
First-time-in-man and pharmacokinetic study of weekly oral perifosine in patients with solid tumours.
Topics: Abdominal Pain; Administration, Oral; Antiemetics; Antineoplastic Agents; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Phosphorylcholine; Treatment Outcome; Vomiting | 2010 |
Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Oligopeptides; Phosphorylcholine; Prognosis; Proto-Oncogene Proteins c-akt; Recurrence; Waldenstrom Macroglobulinemia | 2010 |
Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Double-Blind Method; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Phosphorylcholine | 2011 |
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Phosphorylcholine; Pyrazines; Recurrence | 2011 |
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Grading; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Phosphorylcholine; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Taxoids | 2012 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Phosphatidylinositol 3-Kinase; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Thalidomide; Treatment Outcome | 2012 |
Two phase 2 trials of the novel Akt inhibitor perifosine in patients with advanced renal cell carcinoma after progression on vascular endothelial growth factor-targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylcholine; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Salvage Therapy; Survival Rate; Vascular Endothelial Growth Factor A | 2012 |
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Staurosporine; Treatment Outcome; Young Adult | 2013 |
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cell Survival; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Treatment Outcome | 2014 |
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Area Under Curve; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Phosphorylcholine; Treatment Outcome; Young Adult | 2014 |
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult | 2014 |
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Male; Neoplasm Recurrence, Local; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Young Adult | 2017 |
Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Phosphorylcholine; Prognosis; Proto-Oncogene Proteins c-akt; Salvage Therapy; Signal Transduction; Survival Rate; Young Adult | 2017 |
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Topics: Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioma; Humans; Hyperuricemia; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Neutropenia; Phosphorylcholine; Sarcoma, Ewing; Treatment Outcome; Wilms Tumor | 2017 |
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Female; Follow-Up Studies; Genital Neoplasms, Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Phosphorylcholine; Prognosis | 2017 |
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-akt; Survival Rate; Young Adult | 2019 |
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine; Prospective Studies; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2020 |
174 other study(ies) available for perifosine and phosphorylcholine
| Article | Year |
|---|---|
D-21266, a new heterocyclic alkylphospholipid with antitumour activity.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Body Weight; Dose-Response Relationship, Drug; Female; Mammary Neoplasms, Experimental; Phosphorylcholine; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured | 1997 |
Physical properties and pharmacological activity in vitro and in vivo of optimised liposomes prepared from a new cancerostatic alkylphospholipid.
Topics: Animals; Breast Neoplasms; Cell Division; Female; Humans; Liposomes; Metallothionein 3; Mice; Mice, Nude; Phosphorylcholine; Tumor Cells, Cultured | 1998 |
Quantification of perifosine, an alkylphosphocholine anti-tumour agent, in plasma by pneumatically assisted electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Phosphorylcholine; Quality Control; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet | 1999 |
Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis.
Topics: Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Endothelium, Vascular; Gamma Rays; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phospholipid Ethers; Phosphorylcholine; Protein Kinases; Signal Transduction; U937 Cells | 1999 |
BCR-ABL influences the antileukaemic efficacy of alkylphosphocholines.
Topics: Apoptosis; Cell Adhesion; Cell Survival; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Molecular Structure; Phosphorylcholine; Structure-Activity Relationship; Tumor Cells, Cultured | 1999 |
Effect of the anti-neoplastic agents edelfosine (ET-18-OCH3), ilmofosine (BM 41.440) and the hexadecylphosphocholine analogues D-20133 and D-21266 on histamine release from isolated rat mast cells.
Topics: Animals; Antineoplastic Agents; Calcimycin; Histamine Release; Ionophores; Male; Mast Cells; Phorbol Esters; Phospholipid Ethers; Phosphorylcholine; Piperidines; Rats; Rats, Wistar | 1999 |
Quantitative determination of perifosine, a novel alkylphosphocholine anticancer agent, in human plasma by reversed-phase liquid chromatography-electrospray mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Phosphorylcholine; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2001 |
Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Cell Cycle; Cholesterol; Drug Screening Assays, Antitumor; Endocytosis; Humans; Phospholipids; Phosphorylcholine; Tumor Cells, Cultured | 2001 |
Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2 Protein Kinase; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; DNA; Head and Neck Neoplasms; Humans; Phosphorylcholine; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
ACCESS oncology and Zentaris sign product partnership.
Topics: Clinical Trials, Phase II as Topic; Cooperative Behavior; Drug Industry; Humans; Neoplasms; Phosphorylcholine | 2002 |
Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway.
Topics: Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Growth Inhibitors; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 12; Mitogen-Activated Protein Kinases; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Phospholipid Ethers; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction | 2003 |
Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation.
Topics: Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Male; Molecular Structure; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation | 2003 |
Synthesis and antiproliferative activity of alkylphosphocholines.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; HeLa Cells; Hemolysis; Humans; Inhibitory Concentration 50; Jurkat Cells; K562 Cells; Macrophages; Mice; Molecular Structure; Phospholipase D; Phosphorylcholine; Structure-Activity Relationship; Tetrazolium Salts; Thymidine | 2003 |
Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/cip1) promoter by Sp1.
Topics: Alkylation; Base Sequence; Binding Sites; Cell Line; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Gene Expression Regulation; Humans; Keratinocytes; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutagenesis; Phospholipids; Phosphorylcholine; Promoter Regions, Genetic; Sp1 Transcription Factor; Transcriptional Activation | 2004 |
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bromodeoxyuridine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoblotting; Lung Neoplasms; Male; Phosphorylcholine; Prostatic Neoplasms; Signal Transduction; Staurosporine; Time Factors | 2004 |
Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Butyrates; Cell Growth Processes; Cell Line, Tumor; Ceramides; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Leukemia; MAP Kinase Signaling System; Mitochondria; Mitogen-Activated Protein Kinase 3; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Vorinostat | 2005 |
Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Female; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylcholine; Tissue Distribution; Vulvar Neoplasms | 2005 |
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; CDC2-CDC28 Kinases; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Dacarbazine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase; G2 Phase; Glioma; Humans; Mice; Mice, Transgenic; Phosphorylcholine; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Temozolomide; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2005 |
Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C225 by perifosine in PTEN-deficient cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase | 2006 |
Synthesis and biological evaluation of spin-labeled alkylphospholipid analogs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cyclic N-Oxides; Drug Screening Assays, Antitumor; Hemolysis; Humans; Liposomes; Micelles; Organophosphates; Phospholipids; Phosphorylcholine; Solutions; Spin Labels; Structure-Activity Relationship; Surface-Active Agents | 2005 |
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Topics: Cell Division; Cell Line, Tumor; Flow Cytometry; Growth Substances; Humans; Multiple Myeloma; Oncogene Protein v-akt; Phosphorylation; Phosphorylcholine | 2006 |
Radiosensitization of squamous cell carcinoma by the alkylphospholipid perifosine in cell culture and xenografts.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; G2 Phase; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylcholine; Radiation-Sensitizing Agents; Rhodamines; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay; X-Rays | 2006 |
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Combined Modality Therapy; Female; Glioma; Humans; Immunohistochemistry; Mice; Mice, Nude; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2006 |
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways.
Topics: Apoptosis; Drug Combinations; Drug Synergism; Enzyme Activation; Etoposide; fas Receptor; Humans; Jurkat Cells; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction | 2006 |
Perifosine may be of therapeutic usefulness in morbid obese females via inhibition of the PI3K/Akt signaling pathway.
Topics: Enzyme Activation; Female; Humans; Obesity, Morbid; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction | 2007 |
Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts.
Topics: Apoptosis; Caspase 8; Cell Line, Tumor; Cell Proliferation; fas Receptor; Fas-Associated Death Domain Protein; Humans; Membrane Microdomains; Multiple Myeloma; Phospholipid Ethers; Phosphorylcholine; Signal Transduction; Structure-Activity Relationship | 2007 |
In vitro activity of perifosine: a novel alkylphospholipid against the promastigote stage of Leishmania species.
Topics: Animals; Antiprotozoal Agents; Humans; Inhibitory Concentration 50; Leishmania; Phosphorylcholine | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on hematological therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Boronic Acids; Bortezomib; Hematologic Neoplasms; Hematology; Humans; Indoles; Janus Kinase 2; Lactams, Macrocyclic; Myeloproliferative Disorders; Phosphorylcholine; Pyrazines | 2007 |
A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids.
Topics: Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Membrane; Dimerization; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Green Fluorescent Proteins; Leishmania infantum; Phosphatidylcholines; Phospholipid Ethers; Phosphorylcholine; Saccharomyces cerevisiae; Transformation, Genetic | 2007 |
Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
Topics: Animals; Apoptosis; Cell Line; Female; Hematopoiesis; Humans; Hyperplasia; Leukocytosis; Mice; Multiple Myeloma; Myeloid Cells; Phosphorylcholine; Thrombocytosis | 2007 |
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2007 |
A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endocytosis; HeLa Cells; Humans; Lymphoma; Membrane Microdomains; Mice; Phosphatidylcholines; Phospholipid Ethers; Phospholipids; Phosphorylcholine; Sphingomyelins; Time Factors | 2007 |
Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
Topics: Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Inhibitor of Apoptosis Proteins; Mice; Microtubule-Associated Proteins; Models, Animal; Multiple Myeloma; Neoplasm Proteins; Neoplasm Transplantation; Phosphorylcholine; Protease Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; RNA Interference; RNA, Small Interfering; Survivin; Transplantation, Heterologous | 2007 |
The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
Topics: Animals; Cell Adhesion; Cell Movement; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation; Waldenstrom Macroglobulinemia | 2007 |
Lipid rafts and metabolic energy differentially determine uptake of anti-cancer alkylphospholipids in lymphoma versus carcinoma cells.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; KB Cells; Lymphoma; Membrane Microdomains; Mice; Phospholipid Ethers; Phospholipids; Phosphorylcholine | 2007 |
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Topics: Apoptosis; bcl-Associated Death Protein; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Fas Ligand Protein; fas Receptor; Flow Cytometry; fms-Like Tyrosine Kinase 3; Humans; Immunoprecipitation; Leukemia, Myeloid, Acute; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2008 |
Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Glycine max; Humans; Inhibitory Concentration 50; Isoflavones; Male; Phosphorylation; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Polysaccharides; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, Androgen; RNA, Small Interfering; Transfection | 2007 |
The anti-tumor alkylphospholipid perifosine is internalized by an ATP-dependent translocase activity across the plasma membrane of human KB carcinoma cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Membrane; Clathrin; Dynamin I; Endocytosis; Humans; Phospholipid Transfer Proteins; Phosphorylcholine; RNA, Small Interfering | 2008 |
Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents.
Topics: Alkylation; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Capillaries; Cattle; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Humans; Indicators and Reagents; Phosphodiesterase Inhibitors; Phospholipid Ethers; Phospholipids; Phosphorylcholine | 2008 |
Pharmacodynamic markers of perifosine efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; Immunoblotting; Mice; Mice, Nude; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Transfection; Xenograft Model Antitumor Assays | 2007 |
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
Topics: Benzoquinones; Bone Marrow; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; DNA Replication; Flow Cytometry; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2008 |
Targeting NF-kappaB in Waldenstrom macroglobulinemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; NF-kappa B; Phosphorylcholine; Pyrazines; Signal Transduction; Waldenstrom Macroglobulinemia | 2008 |
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Topics: Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Enzyme Activation; Epidermal Growth Factor; Erlotinib Hydrochloride; Flow Cytometry; Humans; Male; Morpholines; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Caspases; Cell Survival; Cytochromes c; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Humans; Immunoenzyme Techniques; JNK Mitogen-Activated Protein Kinases; Leukemia-Lymphoma, Adult T-Cell; Membrane Microdomains; Mitochondria; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Vinblastine | 2008 |
Perifosine induces differentiation and cell death in prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Androgens; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; Cyclic AMP Response Element-Binding Protein; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Neoplasms, Hormone-Dependent; Phosphorylcholine; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2008 |
Perifosine inhibits growth of human experimental endometrial cancers by blockade of AKT phosphorylation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Endometrial Neoplasms; Female; Humans; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2008 |
Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Drug Synergism; Flow Cytometry; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptors, Death Domain; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2008 |
In vivo activity of perifosine against Leishmania amazonensis.
Topics: Administration, Oral; Animals; Antiprotozoal Agents; Female; Leishmania mexicana; Leishmaniasis, Cutaneous; Mice; Mice, Inbred BALB C; Phospholipid Ethers; Phosphorylcholine; Survival Analysis | 2008 |
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells.
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Survival; Drug Synergism; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinase 9; Phosphorylcholine; Protein Kinase C; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-jun; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein | 2008 |
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Dipyridamole; Drug Combinations; Female; Humans; Liposomes; Lung Neoplasms; Metallothionein 3; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Cells, Circulating; Phosphorylcholine; Platelet Aggregation Inhibitors | 2009 |
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Genome, Human; Humans; MAP Kinase Signaling System; Oligonucleotide Array Sequence Analysis; Phosphorylcholine; Polymorphism, Single Nucleotide; Sarcoma; Software | 2008 |
[Akt enzyme: new therapeutic target in cancer and diabetes?].
Topics: Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Diabetes Mellitus; Enzyme Activation; Humans; Hypoglycemic Agents; Insulin Resistance; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Ribonucleosides | 2009 |
Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
Topics: Animals; Antineoplastic Agents; Blood Coagulation; Blood Vessels; Cell Line, Tumor; Dipyridamole; Female; Fibrin; Humans; Liposomes; Lung; Lung Neoplasms; Mammary Neoplasms, Experimental; Metallothionein 3; Mice; Mice, Nude; Neoplasm Metastasis; Phosphorylcholine; Platelet Aggregation Inhibitors; Xenograft Model Antitumor Assays | 2010 |
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Boronic Acids; Bortezomib; Caspase 10; Caspase 8; Cell Line, Tumor; Drug Synergism; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Fluorescent Antibody Technique; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; Leukemia, T-Cell; Membrane Microdomains; Microscopy, Confocal; Mitochondria; Multiple Myeloma; Phosphorylcholine; Pyrazines; Resveratrol; Signal Transduction; Stilbenes | 2009 |
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Humans; Mice; Mice, Nude; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinases; RNA, Small Interfering; Signal Transduction; Sirolimus; Thyroid Neoplasms; TOR Serine-Threonine Kinases; Transfection; Xenograft Model Antitumor Assays | 2009 |
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gene Silencing; Humans; Immunohistochemistry; Lung Neoplasms; Phosphorylcholine; Pyrazoles; RNA, Small Interfering; Sulfonamides | 2009 |
The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Child; Cyclin-Dependent Kinase Inhibitor p21; Etoposide; Humans; Isoenzymes; Medulloblastoma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Transfection | 2009 |
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
Topics: Animals; Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Chloroquine; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Glycogen Synthase Kinase 3; HCT116 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Protein v-akt; Phosphorylation; Phosphorylcholine; Protein Kinases; Signal Transduction; TOR Serine-Threonine Kinases; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2009 |
Perifosine plus nutlin-3 combination shows a synergistic anti-leukaemic activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Death; Drug Screening Assays, Antitumor; Humans; Imidazoles; Leukemia; Phosphorylcholine; Piperazines; Tumor Cells, Cultured | 2010 |
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways.
Topics: Cell Line, Tumor; Gene Expression Regulation; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Iodine Radioisotopes; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Symporters; Thyroid Gland; Thyroid Neoplasms; Thyrotropin; TOR Serine-Threonine Kinases; Vorinostat | 2010 |
Perifosine selectively induces cell cycle block and modulates retinoblastoma and E2F1 protein levels in p53 mutated leukemic cell lines.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; Humans; Leukemia; Mutation; Phosphorylcholine; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2011 |
Selective targeting of radiation-resistant tumor-initiating cells.
Topics: Animals; Cell Separation; DNA Damage; DNA Repair; Female; Flow Cytometry; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Mutant Strains; Neoplastic Stem Cells; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Tumor Suppressor Protein p53; Wnt Proteins | 2010 |
Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma.
Topics: Animals; Brain Stem Neoplasms; Combined Modality Therapy; Disease Models, Animal; Genetic Engineering; Glioma; Inbreeding; Mice; Mice, Inbred BALB C; Phosphorylcholine; Receptor, Platelet-Derived Growth Factor alpha | 2010 |
Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Cytokines; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lymphoma, Primary Effusion; Mice; Mice, Inbred NOD; Mice, SCID; Paracrine Communication; Phosphoinositide-3 Kinase Inhibitors; Phosphorylcholine; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Rosiglitazone; Thiazolidinediones; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Perifosine-related rapidly progressive corneal ring infiltrate.
Topics: Corneal Opacity; Disease Progression; Female; Humans; Keratoplasty, Penetrating; Middle Aged; Phosphorylcholine; Waldenstrom Macroglobulinemia | 2010 |
[Waldenström's macroglobulinemia].
Topics: Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Diagnosis, Differential; Humans; Male; Nucleosides; Phosphorylcholine; Prognosis; Protease Inhibitors; Pyrazines; Rituximab; Waldenstrom Macroglobulinemia | 2010 |
Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
Topics: Albumins; Animals; Apoptosis; Autophagy; Bone Marrow Cells; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Humans; Insulin-Like Growth Factor I; Interleukin-6; Intracellular Signaling Peptides and Proteins; Mice; Multiple Myeloma; Nanoparticles; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Cisplatin; Cysteine Proteinase Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2011 |
Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membrane-targeted alkylphospholipid analogues.
Topics: Antineoplastic Agents; Biological Transport; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Cholesterol; Drug Delivery Systems; Endoplasmic Reticulum; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Liver Neoplasms; Membrane Microdomains; Phospholipid Ethers; Phosphorylcholine; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Getting into the AKT.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Clinical Trials as Topic; Disease Models, Animal; Growth Inhibitors; Humans; Mice; Neuroblastoma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2010 |
In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Clinical Trials as Topic; Disease Models, Animal; Growth Inhibitors; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Luciferases; Luminescent Agents; Mice; Mutation; Neuroblastoma; NIH 3T3 Cells; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Transplantation, Heterologous | 2010 |
CDC50A plays a key role in the uptake of the anticancer drug perifosine in human carcinoma cells.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Membrane; Cell Survival; Chlorocebus aethiops; CHO Cells; COS Cells; Cricetinae; Cricetulus; Dogs; HeLa Cells; Humans; Membrane Proteins; Mice; NIH 3T3 Cells; Phospholipid Transfer Proteins; Phosphorylcholine | 2010 |
Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells.
Topics: Apoptosis; Aromatase; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Estrogen Antagonists; Female; Humans; Phosphorylcholine; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, G-Protein-Coupled; Receptors, Growth Factor; Signal Transduction; Tamoxifen | 2010 |
Fractionated radiation therapy can induce a molecular profile for therapeutic targeting.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose Fractionation, Radiation; Gene Expression Profiling; Histones; Humans; Male; Oligonucleotide Array Sequence Analysis; Phenotype; Phosphorylation; Phosphorylcholine; Prostatic Neoplasms; Radiotherapy Dosage; Reproducibility of Results; Time Factors | 2010 |
Targeting the PI3K/Akt cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds.
Topics: Anti-HIV Agents; Cell Death; Cell Line; Cells, Cultured; HIV Infections; HIV-1; Humans; Macrophages; Phosphatidylinositol 3-Kinases; Phospholipid Ethers; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction | 2010 |
In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; HL-60 Cells; Humans; Immunohistochemistry; Inhibitory Concentration 50; K562 Cells; Ki-67 Antigen; Lenalidomide; Leukemia, Myeloid; Lymphoma; Multiple Myeloma; Phosphorylcholine; Pyrazines; Thalidomide; Time Factors | 2012 |
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Topics: Animals; Anthracenes; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Glutathione; Head and Neck Neoplasms; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; Phosphorylcholine; Reactive Oxygen Species; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Glioblastoma; Mice; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sirolimus | 2011 |
Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Topics: Brain Neoplasms; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Humans; Neuroblastoma; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Receptor, trkB; Tetracycline | 2011 |
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-8; Kidney Neoplasms; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.
Topics: Annexin A5; Antigens, CD34; Boronic Acids; Bortezomib; Caspases; Colony-Forming Units Assay; Doxorubicin; Flow Cytometry; Health; Hematopoietic Stem Cells; Humans; Immunohistochemistry; Lenalidomide; Phosphorylcholine; Pyrazines; Staining and Labeling; Thalidomide; Tissue Donors; Trypan Blue | 2012 |
Perifosine as potential anti-cancer agent inhibits proliferation, migration, and tube formation of human umbilical vein endothelial cells.
Topics: Antineoplastic Agents; Cell Line; Cell Movement; Cyclin B1; G2 Phase; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Vascular Endothelial Growth Factor A | 2012 |
Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Ceramides; Drug Synergism; Female; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases | 2011 |
IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Activation; Female; Gene Deletion; HEK293 Cells; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Mammary Neoplasms, Animal; Mice; Mice, Knockout; NIH 3T3 Cells; Oxadiazoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Ribonucleosides; Trans-Activators; Transcription Factors | 2011 |
CD81 is essential for the re-entry of hematopoietic stem cells to quiescence following stress-induced proliferation via deactivation of the Akt pathway.
Topics: Animals; Cell Proliferation; Enzyme Activation; Flow Cytometry; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Expression Regulation; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Oxidative Stress; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Tetraspanin 28; Transplantation Conditioning | 2011 |
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma; Cell Proliferation; Down-Regulation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Synergism; Glutamic Acid; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Mutant Proteins; Oncogene Protein v-akt; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sulfonamides; Thyroid Neoplasms; Tumor Cells, Cultured; Valine; Vemurafenib | 2012 |
Repression of mammosphere formation of human breast cancer cells by soy isoflavone genistein and blueberry polyphenolic acids suggests diet-mediated targeting of cancer stem-like/progenitor cells.
Topics: Animals; Blueberry Plants; Breast Neoplasms; CD24 Antigen; Cell Line, Tumor; Female; Genistein; Humans; Hyaluronan Receptors; Isoflavones; Mammary Neoplasms, Experimental; Mice; Neoplastic Stem Cells; Phosphorylcholine; Plant Extracts; Polyphenols; PTEN Phosphohydrolase; Soybean Proteins | 2012 |
Metabolic consequences of treatment with AKT inhibitor perifosine in breast cancer cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Choline; Choline Kinase; Choline-Phosphate Cytidylyltransferase; Female; Humans; Lactic Acid; Magnetic Resonance Spectroscopy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Diester Hydrolases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Perifosine downregulates MDR1 gene expression and reverses multidrug-resistant phenotype by inhibiting PI3K/Akt/NF-κB signaling pathway in a human breast cancer cell line.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Elafin; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2012 |
Induction of sodium/iodide symporter (NIS) expression and radioiodine uptake in non-thyroid cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Diphenylamine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Iodine Radioisotopes; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Signal Transduction; Sulfonamides; Symporters; Transcriptional Activation; Vorinostat | 2012 |
Perifosine induces protective autophagy and upregulation of ATG5 in human chronic myelogenous leukemia cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 4; Microtubule-Associated Proteins; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Up-Regulation | 2012 |
Interleukin-6, osteopontin and Raf/MEK/ERK signaling modulate the sensitivity of human myeloma cells to alkylphosphocholines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; MAP Kinase Signaling System; Multiple Myeloma; Organophosphates; Osteopontin; Phosphorylcholine; Proto-Oncogene Proteins c-raf; Quaternary Ammonium Compounds; Signal Transduction; Treatment Outcome | 2012 |
Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caco-2 Cells; Cell Death; Cell Line, Tumor; Cell Proliferation; Ceramides; Colorectal Neoplasms; Curcumin; Cyclin D1; Down-Regulation; Drug Synergism; Endoplasmic Reticulum; Female; HCT116 Cells; HT29 Cells; Humans; I-kappa B Proteins; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, SCID; Multiprotein Complexes; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Phosphorylcholine; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Lysolipid containing liposomes for transendothelial drug delivery.
Topics: Animals; Cell Membrane Permeability; Drug Delivery Systems; Endothelial Cells; Endothelium; Humans; Liposomes; Lysophosphatidylcholines; Models, Biological; Phosphorylcholine | 2012 |
Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Topics: Apoptosis; Bronchial Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Humans; Intestinal Neoplasms; Neoplasm Invasiveness; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphorylcholine; Protein Isoforms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA, Small Interfering | 2012 |
Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Capecitabine; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Dexamethasone; Drug Evaluation, Preclinical; Fluorouracil; Humans; Multiple Myeloma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyrazines; Randomized Controlled Trials as Topic | 2012 |
Perifosine sensitizes UVB-induced apoptosis in skin cells: new implication of skin cancer prevention?
Topics: Apoptosis; Cells, Cultured; Ceramides; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Humans; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Skin; Skin Neoplasms; Structure-Activity Relationship; Ultraviolet Rays | 2012 |
Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; ErbB Receptors; Humans; Mesothelioma; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction | 2012 |
Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Ceramides; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Phosphatidylinositol Phosphates; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, IGF Type 1; RNA Interference; RNA, Small Interfering; Secretory Vesicles; Sphingomyelin Phosphodiesterase; Transplantation, Heterologous | 2012 |
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lung Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Molecular Targeted Therapy; Multiprotein Complexes; Phosphorylation; Phosphorylcholine; Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Everolimus; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; Indoles; Lymphoma, Mantle-Cell; Phosphorylation; Phosphorylcholine; Protein Kinases; Quinolines; Sirolimus | 2012 |
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Linker for activation of T-cell family member2 (LAT2) a lipid raft adaptor protein for AKT signaling, is an early mediator of alkylphospholipid anti-leukemic activity.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 3; Cell Line; Cell Proliferation; Cholesterol; Enzyme Activation; Humans; Leukemia; Membrane Microdomains; Oxides; Phosphatidylinositol 3-Kinases; Phospholipids; Phosphorylcholine; Protein Structure, Tertiary; Proteome; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2012 |
Perifosine induces cell apoptosis in human osteosarcoma cells: new implication for osteosarcoma therapy?
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Osteosarcoma; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2013 |
Synthesis of a phosphinate analogue of the anti-tumour phosphate di-ester perifosine via sequential radical processes.
Topics: Antineoplastic Agents; Esters; Free Radicals; Hydrolysis; Phosphines; Phosphinic Acids; Phosphorylcholine | 2013 |
Invasion in follicular thyroid cancer cell lines is mediated by EphA2 and pAkt.
Topics: Adenocarcinoma, Follicular; Cell Line, Tumor; Humans; Immunoblotting; Neoplasm Invasiveness; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptor, EphA2; RNA, Small Interfering; Thyroid Neoplasms; Tumor Cells, Cultured | 2012 |
Edelfosine and perifosine disrupt hepatic mitochondrial oxidative phosphorylation and induce the permeability transition.
Topics: Animals; Antineoplastic Agents; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitochondrial Membranes; Oxidative Phosphorylation; Permeability; Phospholipid Ethers; Phosphorylcholine; Rats, Wistar | 2013 |
MicroRNA-27a inhibitors alone or in combination with perifosine suppress the growth of gastric cancer cells.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Female; Gene Expression; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotides, Antisense; Phosphorylcholine; Stomach Neoplasms | 2013 |
Influence of cancerostatic perifosine on membrane fluidity of liposomes and different cell lines as measured by electron paramagnetic resonance.
Topics: Animals; Antineoplastic Agents; Cell Membrane; Drug Resistance, Neoplasm; Electron Spin Resonance Spectroscopy; Fibroblasts; Humans; Liposomes; Membrane Fluidity; Metallothionein 3; Mice; Phosphorylcholine; Spin Labels; Tumor Cells, Cultured | 2012 |
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Leukemia, Myeloid, Acute; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Oxazoles; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Synthesis, characterization and Akt phosphorylation inhibitory activity of cyclopentanecarboxylate-substituted alkylphosphocholines.
Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Humans; Neoplasms; Phospholipid Ethers; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt | 2013 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Down-Regulation; Eukaryotic Initiation Factor-4E; Female; Gene Expression; Humans; Inhibitory Concentration 50; Lymphatic Metastasis; Male; Middle Aged; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Up-Regulation | 2013 |
Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.
Topics: Analysis of Variance; Animals; Antigens, CD34; Blotting, Western; Cell Line, Tumor; DNA Primers; Endothelial Cells; Female; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation; Hematopoietic Stem Cell Transplantation; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neovascularization, Pathologic; Phosphorylcholine; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Perifosine inhibits lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α production via regulation multiple signaling pathways: new implication for Kawasaki disease (KD) treatment.
Topics: Animals; Cell Line; Enzyme Activation; Lipopolysaccharides; Macrophages; Mice; Mucocutaneous Lymph Node Syndrome; Phosphorylcholine; Protein Kinases; Signal Transduction; Tumor Necrosis Factor-alpha | 2013 |
Role of CIP4 in high glucose induced epithelial--mesenchymal transition of rat peritoneal mesothelial cells.
Topics: Actins; Animals; Cadherins; Cells, Cultured; Dialysis Solutions; Disease Models, Animal; Epithelial-Mesenchymal Transition; Epithelium; Gene Expression Profiling; Glucose; Male; Microtubule-Associated Proteins; Minor Histocompatibility Antigens; Peritoneal Dialysis; Peritoneal Fibrosis; Peritoneum; Phosphorylcholine; Rats; Rats, Wistar; RNA, Small Interfering; Transfection | 2013 |
Perifosine, an AKT inhibitor, modulates ovarian cancer cell line sensitivity to cisplatin-induced growth arrest.
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; Humans; Neoplasms, Glandular and Epithelial; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA; Signal Transduction | 2013 |
AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers.
Topics: Adenocarcinoma; Adult; Aged; Cell Adhesion Molecules; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Cyclin D1; Down-Regulation; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Membrane Proteins; Middle Aged; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; Signal Transduction; Stomach Diseases; Stomach Neoplasms; Up-Regulation | 2013 |
The short chain cell-permeable ceramide (C6) restores cell apoptosis and perifosine sensitivity in cultured glioblastoma cells.
Topics: Apoptosis; Autophagy; Brain Neoplasms; Cell Membrane Permeability; Cell Proliferation; Cell Survival; Ceramides; Glioblastoma; HEK293 Cells; Humans; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
Cytotoxic amphiphiles and phosphoinositides bind to two discrete sites on the Akt1 PH domain.
Topics: Antineoplastic Agents; Binding Sites; Humans; Micelles; Models, Molecular; Nuclear Magnetic Resonance, Biomolecular; Phosphatidylinositols; Phosphorylcholine; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Spin Labels | 2014 |
Inhibition of hedgehog signaling by GANT58 induces apoptosis and shows synergistic antitumor activity with AKT inhibitor in acute T cell leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Drug Screening Assays, Antitumor; Drug Synergism; Hedgehog Proteins; Humans; Jurkat Cells; MAP Kinase Signaling System; Oxadiazoles; Phosphorylcholine; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-akt; Pyridines; Thiophenes; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2014 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Random Allocation; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
TEIF associated centrosome activity is regulated by EGF/PI3K/Akt signaling.
Topics: Adaptor Proteins, Vesicular Transport; Amino Acid Sequence; Cell Line; Centrioles; Centrosome; DNA-Binding Proteins; Epidermal Growth Factor; Green Fluorescent Proteins; Humans; Molecular Sequence Data; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphorylcholine; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors | 2014 |
Perifosine induced release of contents of trans cell-barrier transport efficient liposomes.
Topics: Biomimetic Materials; Cell Membrane; Computer Simulation; Diffusion; Liposomes; Membrane Fluidity; Models, Chemical; Phosphorylcholine; Static Electricity | 2014 |
Antitumour effect and modulation of expression of the ABCB1 gene by perifosine in canine lymphoid tumour cell lines.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Dogs; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Lymphoma; Phosphorylcholine; Polymerase Chain Reaction; Signal Transduction; Vault Ribonucleoprotein Particles | 2014 |
Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition.
Topics: Aminopyridines; Apoptosis; Breast Neoplasms; DNA-Binding Proteins; Female; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; MCF-7 Cells; Morpholines; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection | 2014 |
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Nitriles; Phosphorylcholine; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Sulfones; Transcription Factor RelA; Transcription Factors; Transplantation, Heterologous; Treatment Outcome | 2015 |
Toxicity evaluation of prolonged convection-enhanced delivery of small-molecule kinase inhibitors in naïve rat brainstem.
Topics: Animals; Antineoplastic Agents; Brain Stem; Convection; Dasatinib; Drug Delivery Systems; Everolimus; Female; Infusions, Intraventricular; Phosphorylcholine; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Sirolimus; Thiazoles | 2015 |
Receptors for luteinizing hormone-releasing hormone (GnRH) as therapeutic targets in triple negative breast cancers (TNBC).
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Receptors, LHRH; Triple Negative Breast Neoplasms; Triptorelin Pamoate | 2015 |
In vitro and in vivo anti-schistosomal activity of the alkylphospholipid analog edelfosine.
Topics: Animals; Antineoplastic Agents; Antiparasitic Agents; Apoptosis; Female; Mice; Phospholipid Ethers; Phosphorylcholine; Schistosoma mansoni; Schistosomiasis mansoni | 2014 |
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caenorhabditis elegans; Cell Line, Tumor; Cholesterol; Drug Resistance; Embryo, Nonmammalian; Embryonic Development; Humans; Insulin-Like Growth Factor I; Larva; Membrane Microdomains; Phospholipid Ethers; Phosphorylcholine | 2014 |
Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Ovarian Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.
Topics: Animals; Animals, Newborn; Brain Stem; Cell Line, Tumor; Cell Proliferation; Convection; Dasatinib; Dose-Response Relationship, Drug; Drug Delivery Systems; Everolimus; Glioma; Intracranial Hemorrhages; Mice; Phosphorylcholine; Protein Kinase Inhibitors; Time Factors | 2015 |
Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model.
Topics: Administration, Oral; Animals; Macaca mulatta; Male; Models, Animal; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2015 |
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Cycle Checkpoints; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Heterocyclic Compounds, 3-Ring; Humans; Jurkat Cells; Molecular Targeted Therapy; Oxadiazoles; Phosphatidylinositol 3-Kinase; Phosphorylation; Phosphorylcholine; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
Decreased carboxylesterases expression and hydrolytic activity in type 2 diabetic mice through Akt/mTOR/HIF-1α/Stra13 pathway.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Blood Glucose; Carboxylic Ester Hydrolases; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Knockdown Techniques; Glucose; Hep G2 Cells; Hepatocytes; Homeodomain Proteins; Humans; Hydrolysis; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Intestines; Liver; Male; Mice, Inbred C57BL; Overweight; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Cholesterol homeostasis and autophagic flux in perifosine-treated human hepatoblastoma HepG2 and glioblastoma U-87 MG cell lines.
Topics: Autophagy; Brain Neoplasms; Cell Line, Tumor; Cholesterol; Glioblastoma; Hepatoblastoma; Homeostasis; Humans; Liver Neoplasms; Phosphorylcholine | 2015 |
How perifosine affects liposome-encapsulated drug delivery across a cell barrier.
Topics: Biological Transport; Cell Membrane; Cells, Cultured; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Liberation; Fluoresceins; Humans; Liposomes; Phosphorylcholine | 2015 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
Topics: Antibodies, Monoclonal; Apoptosis; Cell Line, Tumor; Drug Synergism; Gangliosides; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Quinolines; Quinoxalines; Signal Transduction; Sulfonamides; TOR Serine-Threonine Kinases | 2015 |
Preclinical evaluation of perifosine as a potential promising anti-rhabdomyosarcoma agent.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Rhabdomyosarcoma; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Perifosine as a potential novel anti-telomerase therapy.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Phosphorylcholine; Telomerase; Telomere; Xenograft Model Antitumor Assays | 2015 |
Low-concentration of perifosine surprisingly protects cardiomyocytes from oxygen glucose deprivation.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Glucose; Mice; Myocytes, Cardiac; Oxidative Stress; Phosphorylcholine; Rats | 2016 |
Substance P enhances tissue factor release from granulocyte-macrophage colony-stimulating factor-dependent macrophages via the p22phox/β-arrestin 2/Rho A signaling pathway.
Topics: Acetophenones; Adipocytes; Amides; Aprepitant; Arrestins; Benzopyrans; beta-Arrestin 2; beta-Arrestins; Dynamins; Free Radical Scavengers; Gene Expression Regulation; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Macrophage Activation; Macrophages; Morpholines; NADPH Oxidases; Neurokinin-1 Receptor Antagonists; Phosphorylcholine; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; rho-Associated Kinases; RNA, Small Interfering; Signal Transduction; Substance P; Thiocarbamates; Thromboplastin | 2016 |
Modulation of the voltage-gated potassium channel Kv2.1 by the anti-tumor alkylphospholipid perifosine.
Topics: Antineoplastic Agents; Cell Line; HEK293 Cells; Humans; Ion Channel Gating; Kinetics; Membrane Potentials; Patch-Clamp Techniques; Phosphorylcholine; Potassium; Potassium Channels, Voltage-Gated; Shab Potassium Channels | 2016 |
Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nitrophenols; Phosphorylcholine; Piperazines; Sulfonamides; Treatment Outcome | 2016 |
The alkylphospholipid edelfosine shows activity against Strongyloides venezuelensis and induces apoptosis-like cell death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Dose-Response Relationship, Drug; Female; Larva; Mice; Phospholipid Ethers; Phosphorylcholine; Strongyloides; Strongyloidiasis | 2016 |
Icariside II activates EGFR-Akt-Nrf2 signaling and protects osteoblasts from dexamethasone.
Topics: Animals; Cell Line; Cell Proliferation; Cell Survival; Chromones; Dexamethasone; ErbB Receptors; Flavonoids; Heterocyclic Compounds, 3-Ring; Mice; Morpholines; NF-E2-Related Factor 2; Osteoblasts; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction | 2017 |
Perifosine Mechanisms of Action in Leishmania Species.
Topics: Adenosine Triphosphate; Antiprotozoal Agents; Apoptosis; Gene Expression; Inhibitory Concentration 50; Leishmania donovani; Leishmania mexicana; Membrane Potential, Mitochondrial; Mitochondria; Phosphatidylserines; Phosphorylation; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Protozoan Proteins | 2017 |
Proteome and Acetylome Analysis Identifies Novel Pathways and Targets Regulated by Perifosine in Neuroblastoma.
Topics: Acetylation; Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Chromatography, Liquid; Humans; Lysine; Metabolic Networks and Pathways; Neuroblastoma; Phosphorylcholine; Proteome; Tandem Mass Spectrometry | 2017 |
Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Benzaldehydes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colony-Forming Units Assay; Humans; Lung Neoplasms; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Phosphorylcholine; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; Retinal Dehydrogenase; Signal Transduction; Spheroids, Cellular; Vanilla | 2017 |
Plasma and cerebrospinal fluid pharmacokinetics of select chemotherapeutic agents following intranasal delivery in a non-human primate model.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Blood-Brain Barrier; Dacarbazine; Disease Models, Animal; Macaca mulatta; Male; Nasal Absorption; Phosphorylcholine; Temozolomide; Valproic Acid | 2017 |
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Energy Metabolism; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mitochondria; Paclitaxel; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Triggering of Eryptosis, the Suicidal Erythrocyte Death, by Perifosine.
Topics: Aniline Compounds; Calcium; Cell Size; Ceramides; Eryptosis; Erythrocyte Membrane; Erythrocytes; Flow Cytometry; Hemolysis; Humans; Imidazoles; Phosphatidylserines; Phosphorylcholine; Pyridines; Reactive Oxygen Species; Staurosporine; Xanthenes | 2017 |
Perifosine enhances bevacizumab-induced apoptosis and therapeutic efficacy by targeting PI3K/AKT pathway in a glioblastoma heterotopic model.
Topics: Animals; Apoptosis; Bevacizumab; Caspase 3; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Matrix Metalloproteinase 2; Mice; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2017 |
Akt Inhibitor Perifosine Prevents Epileptogenesis in a Rat Model of Temporal Lobe Epilepsy.
Topics: Animals; Anticonvulsants; Brain; Convulsants; Disease Models, Animal; Epilepsy, Temporal Lobe; Kainic Acid; Male; Neurons; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Status Epilepticus | 2018 |
Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Forkhead Box Protein O1; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Inhibitory Concentration 50; Mesothelioma; Oxadiazoles; Phosphorylation; Phosphorylcholine; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinoxalines; Sulfonamides; Thiadiazoles; Thiophenes | 2017 |
PI3K-Akt Signal Transduction Molecules Maybe Involved in Downregulation of Erythroblasts Apoptosis and Perifosine Increased Its Apoptosis in Chronic Mountain Sickness.
Topics: Adult; Altitude Sickness; Apoptosis; bcl-X Protein; Bone Marrow Cells; Caspase 9; Celecoxib; China; Chronic Disease; Down-Regulation; Erythroblasts; Humans; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Signal Transduction | 2017 |
c-Src activity is differentially required by cancer cell motility modes.
Topics: Actins; Amino Acid Substitution; Butadienes; Cell Adhesion; Cell Movement; Dasatinib; Humans; Imidazoles; Mutant Proteins; Neoplasms; Nitriles; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinolines; Tumor Cells, Cultured | 2018 |
Silencing of NADPH Oxidase 4 Attenuates Hypoxia Resistance in Neuroblastoma Cells SH-SY5Y by Inhibiting PI3K/Akt-Dependent Glycolysis.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Silencing; Glycolysis; Humans; Hypoxia; Insulin-Like Growth Factor I; Membrane Potential, Mitochondrial; NADPH Oxidase 4; Neuroblastoma; Neurons; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction | 2019 |
AKT Inhibition Modulates H3K4 Demethylase Levels in PTEN-Null Prostate Cancer.
Topics: Acetylation; Animals; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Jumonji Domain-Containing Histone Demethylases; Male; Methylation; Mice; MicroRNAs; Nuclear Proteins; Phosphorylcholine; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Repressor Proteins; Xenograft Model Antitumor Assays | 2019 |
Reductive Stress Selectively Disrupts Collagen Homeostasis and Modifies Growth Factor-independent Signaling Through the MAPK/Akt Pathway in Human Dermal Fibroblasts.
Topics: Antioxidants; Collagen; Dermis; Dithiothreitol; Down-Regulation; Endoplasmic Reticulum Stress; Extracellular Matrix Proteins; Fibroblasts; Homeostasis; Humans; Mitogen-Activated Protein Kinases; Oxidation-Reduction; Phosphorylation; Phosphorylcholine; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
The lipid raft protein NTAL participates in AKT signaling in mantle cell lymphoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Phosphorylcholine; Prognosis; Proto-Oncogene Proteins c-akt; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
A novel UCHL
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Phosphorylcholine; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase; Radiation, Ionizing; Recombinational DNA Repair; RNA, Guide, Kinetoplastida; Transplantation, Heterologous; Triple Negative Breast Neoplasms; Ubiquitin Thiolesterase; Ubiquitination | 2019 |
Inhibitors of AKT kinase increase LDL receptor mRNA expression by two different mechanisms.
Topics: Aminopyridines; Animals; Benzimidazoles; CHO Cells; Cricetinae; Cricetulus; Hep G2 Cells; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Phosphorylcholine; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptors, LDL; Ribonucleosides; RNA Stability; RNA, Messenger; Transcriptional Activation | 2019 |
Combination treatment of perifosine and valsartan showed more efficiency in protecting against pressure overload induced mouse heart failure.
Topics: Animals; Disease Models, Animal; Drug Therapy, Combination; Glycogen Synthase Kinase 3 beta; Heart Failure; Male; MAP Kinase Signaling System; Mice, Inbred C57BL; Organ Size; Phosphorylcholine; Pressure; Proto-Oncogene Proteins c-akt; Signal Transduction; Valsartan | 2020 |
Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs.
Topics: Administration, Intravenous; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Stability; Hemolysis; Humans; Maximum Tolerated Dose; Neoplasms; Organophosphates; Phosphorylcholine; Prodrugs; Quaternary Ammonium Compounds | 2020 |
MicroRNA analysis of NCI-60 human cancer cells indicates that miR-720 and miR-887 are potential therapeutic biomarkers for breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Female; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Phosphorylcholine; Survival Analysis; Up-Regulation | 2020 |
Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caco-2 Cells; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Mutation; Oxaliplatin; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
PolyI:C suppresses TGF-β1-induced Akt phosphorylation and reduces the motility of A549 lung carcinoma cells.
Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Lung Neoplasms; Organometallic Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Phosphorylcholine; Poly I-C; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Recombinant Proteins; Signal Transduction; Toll-Like Receptor 3; Transforming Growth Factor beta1 | 2021 |
Synergistic cytotoxicity of perifosine and ABT-737 to colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Humans; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Tumor Microenvironment | 2023 |